Literature DB >> 31575507

Pamrevlumab in idiopathic pulmonary fibrosis.

Athol U Wells1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31575507     DOI： 10.1016/S2213-2600(19)30339-X

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  6 in total

1.  Prognostic Role of NLR, PLR and MHR in Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Yiran Chen; Jingya Cai; Mengmeng Zhang; Xin Yan
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

2.  Blocking CCN2 preferentially inhibits osteoclastogenesis induced by repetitive high force bone loading.

Authors:  Mary F Barbe; Mamta Amin; Anne Gingery; Alex G Lambi; Steven N Popoff
Journal:  Connect Tissue Res       Date:  2020-07-20       Impact factor: 3.417

3.  A Clinical Model for the Prediction of Acute Exacerbation Risk in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Qi Wu; Yong Xu; Ke-Jia Zhang; Shi-Min Jiang; Yao Zhou; Ying Zhao
Journal:  Biomed Res Int       Date:  2020-12-07       Impact factor: 3.411

4.  Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer.

Authors:  Qingqing Sang; Wentao Dai; Junxian Yu; Yunqin Chen; Zhiyuan Fan; Jixiang Liu; Fangyuan Li; Jianfang Li; Xiongyan Wu; Junyi Hou; Beiqin Yu; Haoran Feng; Zheng-Gang Zhu; Liping Su; Yuan-Yuan Li; Bingya Liu
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

5.  Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis.

Authors:  Weibin Qian; Xinrui Cai; Qiuhai Qian; Xinying Zhang
Journal:  Biomed Res Int       Date:  2021-07-04       Impact factor: 3.411

6.  Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury.

Authors:  Mary F Barbe; Brendan A Hilliard; Mamta Amin; Michele Y Harris; Lucas J Hobson; Geneva E Cruz; Steven N Popoff
Journal:  FASEB J       Date:  2020-03-29       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.